Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ALLIANCE PHARMA PLC Share Issue/Capital Change 2013

Jun 12, 2013

7478_rns_2013-06-12_5cee8f61-3bd9-4aee-90bc-74f067a72af9.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9059G

Alliance Pharma PLC

12 June 2013

For immediate release 12 June 2013

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Exercise of Share Options

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that following the exercise of employee share options on 12 June 2013, application has been made by Alliance for a further 205,985 ordinary shares of 1 pence each in the Company ("Ordinary Shares") to be admitted to trading on AIM.

It is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 18 June 2013.

Following the admission of the 205,985 Ordinary Shares, Alliance will have 250,023,628 Ordinary Shares in issue.  

For further information:

### Alliance Pharma plc ### + 44 (0) 1249 466966
John Dawson, Chief Executive Officer
Richard Wright, Finance Director
### Buchanan ### + 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles

www.buchanan.uk.com
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Oliver Cardigan
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections.  Alliance's sales are mainly prescription driven.  Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLFEVRIIFLIV